Invivyd, Inc. IVVD

Company Overview

Invivyd, Inc. is a U.S.-based biotechnology company focused on developing antibody-based therapies for infectious diseases, with a primary emphasis on COVID-19 prevention and treatment. The company operates within the biotechnology and biopharmaceutical industries and uses a proprietary platform designed to rapidly identify and engineer monoclonal antibodies intended to maintain activity against evolving viral variants. Its principal revenue and development focus has centered on COVID-19-related therapeutics, particularly monoclonal antibody candidates designed for immunocompromised and high-risk patient populations.

The company was originally founded as Adagio Therapeutics in 2020 and later rebranded to Invivyd, Inc. as it refined its scientific and commercial strategy. Invivyd’s positioning has been based on its variant-resilient antibody engineering approach and its emphasis on continuous viral surveillance to address rapid SARS‑CoV‑2 mutation patterns. Public disclosures in SEC filings and company presentations indicate that the company’s strategy prioritizes durable antibody therapeutics that may retain efficacy across multiple virus strains, differentiating it from earlier-generation COVID antibody developers whose products lost effectiveness as variants evolved.